Clinical Trial Results:
The effect of the co-administration of multiple oral doses of the fructose-1,6-bisphosphatase (FBPase) inhibitor CS-917 and glibenclamide on pharmacokinetics, safety and tolerability in diabetic patients (NIDDM)
Summary
|
|
EudraCT number |
2004-003195-11 |
Trial protocol |
DE |
Global completion date |
11 May 2005
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
26 Nov 2016
|
First version publication date |
26 Nov 2016
|
Other versions |
|
Summary report(s) |
Report Synopsis CS0917-A-E107 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.